Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Gold Prices Set for Weekly Loss as Iran Tensions and Fed Rate Outlook Weigh 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
US Launches New Iran Strikes as Strait of Hormuz Conflict Escalates, Oil Prices Rise 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
European Regulators Clash With U.S. Treasury Over Private Credit Transparency 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Japan Producer Inflation Hits 7.1% in June, Fueling BOJ Rate Hike Expectations 
Dollar Ends Week Higher as Yen Jumps on Japan Pension Fund Investment Plans 
Venezuela Earthquake Death Toll Climbs to 3,811 as Government Seeks Sanctions Relief 
Fed Reaffirms 2% Inflation Goal, Vows Forceful Action to Anchor Price Expectations 
US Back-to-School Spending Seen Falling as Families Focus on Essentials 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
